Literature DB >> 30760062

Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study.

Zarchi E Sumon1, Charles S Berenson1,2, John A Sellick1,2, Zackery P Bulman3, Brian T Tsuji3, Kari A Mergenhagen4.   

Abstract

Infectious complications following surgical valve replacements are extremely difficult to treat, often requiring prolonged antimicrobials therapy with or without surgery. Vancomycin-intermediate Staphylococcus aureus is an infrequent pathogen, with an estimated prevalence of less than 0.3%, but presents even greater challenges. We report a case of successful cure of daptomycin-non-susceptible and vancomycin-intermediate Staphylococcus aureus prosthetic valve endocarditis using an eight-week course of combination antimicrobial therapy. Using time-kill study, the combination of daptomycin plus ceftaroline and rifampin resulted in a greater than 4 log reduction of bacterial growth at 24 hours. This antimicrobial combination was used for a total of eight weeks with a successful outcome.

Entities:  

Keywords:  Prosthetic valve endocarditis; time-kill study; vancomycin-intermediate

Mesh:

Substances:

Year:  2019        PMID: 30760062     DOI: 10.1080/23744235.2018.1533646

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  2 in total

1.  In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient.

Authors:  Eric Wenzler; Maressa Santarossa; Kevin A Meyer; Amanda T Harrington; Gail E Reid; Nina M Clark; Fritzie S Albarillo; Zackery P Bulman
Journal:  Open Forum Infect Dis       Date:  2020-01-04       Impact factor: 3.835

2.  Glutathione-Conjugated Hydrogels: Flexible Vehicles for Personalized Treatment of Bacterial Infections.

Authors:  Karol Sokolowski; Hai M Pham; Eric Wenzler; Richard A Gemeinhart
Journal:  Pharm Res       Date:  2021-06-11       Impact factor: 4.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.